共 43 条
- [21] Lymphocyte depletion, recovery and efficacy in NZBWF1 lupus mice following continuous or intermittent dosing regimen of Venetoclax (ABT-199), a potent and selective BCL-2 InhibitorCLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015, 33 (03) : S33 - S33Wang, L.Perper, S.Black, K.Mario, R.Graff, C.Hartman, D.Souers, A.Elmore, S.Olson, L.
- [22] Expression of Bcl-2 pro-survival family proteins predicts pharmacological responses to ABT-199, a novel and selective Bcl-2 antagonist, in multiple myeloma modelsCANCER RESEARCH, 2013, 73 (08)Sampath, DeepakPunnoose, ElizabethBeghaert, ErwinBelmont, LisaPeale, FranklinNguyen TanChen, JunDarbonne, WalterYue, PengOeh, JasonLee, LeslieFairbrother, Wayne J.Souers, Andrew J.Elmore, Steven W.Leverson, Joel D.
- [23] Expression of Bcl-2 Pro-Survival Family Proteins Predicts Pharmacological Responses to ABT-199, a Novel and Selective Bc1-2 Antagonist, in Multiple Myeloma ModelsBLOOD, 2012, 120 (21)Sampath, DeepakPunnoose, ElizabethBoghaert, Erwin R.Belmont, LisaChen, JunPeale, FranklinNguyen TanDarbonne, WalterYue, PengOeh, JasonLee, LeslieFairbrother, Wayne J.Souers, Andrew J.Elmore, Steve W.Leverson, Joel D.
- [24] Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b StudyBLOOD, 2015, 126 (23)Ma, ShuoBrander, Danielle M.Seymour, John F.Kipps, Thomas J.Barrientos, Jacqueline C.Davids, Matthew S.Anderson, Mary AnnChoi, Michael Y.Tam, Constantine S.Mason-Bright, TanitaPrine, BettyMunasinghe, WijithZhu, MingKim, Su YoungHumerickhouse, Rod A.Roberts, Andrew W.
- [25] Anti-Leukemia Activity of the BCL-2 INHIBITOR ABT-199 in Pediatric BCP-ALL is Predicted by BCL-2/MCL-1 Expression Indicating Treatment ResponseANNALS OF HEMATOLOGY, 2017, 96 : S79 - S79Seyfried, F.Hoerl, R.Demir, S.Koehrer, S.Scheffold, A.Stilgenbauer, S.Debatin, K-M.Meyer, L. H.
- [26] Activation of p53 By Novel MDM2 Antagonist RG7388 Overcomes AML Inherent and Acquired Resistance to Bcl-2 Inhibitor ABT-199 (GDC-0199)BLOOD, 2014, 124 (21)Pan, RongqingKojima, KensukeZheng, ZhuanzhenRuvolo, Vivian R.Nichols, GwenLeverson, Joel D.Dangl, MarkusKonopleva, MarinaAndreeff, Michael
- [27] A novel kinase inhibitor, LZT-106, downregulates Mcl-1 and sensitizes colorectal cancer cells to BH3 mimetic ABT-199 by targeting CDK9 and GSK-3β signalingCANCER LETTERS, 2021, 498 : 31 - 41Yu, ZhouDu, JiayingZhao, YueGao, YuanLi, YongxuZhao, KaiLu, Na
- [28] A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are ≥ to 65 Years and Not Eligible for Standard Induction TherapyBLOOD, 2015, 126 (23)DiNardo, CourtneyPollyea, DanielPratz, KeithThirman, Michael J.Letai, AnthonyFrattini, MarkJonas, BrianLeverson, JoelZhu, MingDunbar, MartinFalotico, NancyKirby, RachelAgarwal, SureshMabry, MackPotluri, JalajaHumerickhouse, Rod A.Kantarjian, Hagop M.Konopleva, Marina
- [29] Factors associated with remission and relapse in first episode psychosis following treatment with novel antipsychotics and psychosocial interventionsINTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S410 - S410Malla, ANorman, RManchanda, RMcLean, TTakahr, JHaricharan, R
- [30] BCL-2 Inhibitor Venetoclax (ABT-199) and MEK Inhibitor GDC-0973 Synergise to Target AML Progenitors and Overcome Drug Resistance with the Use of PET Scanning in a Mouse Model of HR-MDS to Monitor Response to TreatmentBLOOD, 2018, 132Padua, Rose AnnSarda-Mantel, LaureChiquet, MathieuKappel, ClaireKrief, PatriciaSetterblad, NiclasHontonnou, FortuneHosten, BenoitVignal, NicolasZassadowski, FabienCassinat, BrunoGou, PanhongGiraudier, StephaneKonopleva, Marina Y.Andreeff, MichaelMarika, P. L. A.Ades, LionelFenaux, PierreChomienne, Christine